Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1982 3
1983 2
1984 4
1985 2
1986 1
1987 1
1988 1
1989 1
1990 7
1991 2
1992 2
1993 1
1994 2
1995 1
1996 2
1998 2
2000 1
2001 3
2002 3
2003 2
2004 1
2008 1
2010 1
2013 2
2014 4
2015 2
2016 2
2019 1
2020 1
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

58 results
Results by year
Filters applied: . Clear all
Page 1
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, Pellegrino M, Durruthy-Durruthy R, Watt CD, Asthana S, Lasater EA, DeFilippis R, Peretz CAC, McGary LHF, Deihimi S, Logan AC, Luger SM, Shah NP, Carroll M, Smith CC, Perl AE. McMahon CM, et al. Among authors: lasater ea. Cancer Discov. 2019 Aug;9(8):1050-1063. doi: 10.1158/2159-8290.CD-18-1453. Epub 2019 May 14. Cancer Discov. 2019. PMID: 31088841 Free article.
Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade.
Kohlhapp FJ, Haribhai D, Mathew R, Duggan R, Ellis PA, Wang R, Lasater EA, Shi Y, Dave N, Riehm JJ, Robinson VA, Do AD, Li Y, Orr CJ, Sampath D, Raval A, Merchant M, Bhathena A, Salem AH, Hamel KM, Leverson JD, Donawho C, Pappano WN, Uziel T. Kohlhapp FJ, et al. Among authors: lasater ea. Cancer Discov. 2021 Jan;11(1):68-79. doi: 10.1158/2159-8290.CD-19-0759. Epub 2020 Sep 4. Cancer Discov. 2021. PMID: 32887697 Free article.
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models.
Singh Mali R, Zhang Q, DeFilippis RA, Cavazos A, Kuruvilla VM, Raman J, Mody V, Choo EF, Dail M, Shah NP, Konopleva M, Sampath D, Lasater EA. Singh Mali R, et al. Among authors: lasater ea. Haematologica. 2021 Apr 1;106(4):1034-1046. doi: 10.3324/haematol.2019.244020. Haematologica. 2021. PMID: 32414851 Free PMC article.
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
Ciceri P, Müller S, O'Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, Lasater EA, Pallares G, Picaud S, Wells C, Martin S, Wodicka LM, Shah NP, Treiber DK, Knapp S. Ciceri P, et al. Among authors: lasater ea. Nat Chem Biol. 2014 Apr;10(4):305-12. doi: 10.1038/nchembio.1471. Epub 2014 Mar 2. Nat Chem Biol. 2014. PMID: 24584101 Free PMC article.
MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction.
Asmussen J, Lasater EA, Tajon C, Oses-Prieto J, Jun YW, Taylor BS, Burlingame A, Craik CS, Shah NP. Asmussen J, et al. Among authors: lasater ea. Cancer Discov. 2014 Feb;4(2):200-15. doi: 10.1158/2159-8290.CD-13-0235. Epub 2013 Dec 20. Cancer Discov. 2014. PMID: 24362263 Free PMC article.
Crenolanib is a selective type I pan-FLT3 inhibitor.
Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK, Damon LE, Perl AE, Jeschke GR, Sugita M, Carroll M, Kogan SC, Kuriyan J, Shah NP. Smith CC, et al. Among authors: lasater ea. Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5319-24. doi: 10.1073/pnas.1320661111. Epub 2014 Mar 12. Proc Natl Acad Sci U S A. 2014. PMID: 24623852 Free PMC article.
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.
Minson KA, Smith CC, DeRyckere D, Libbrecht C, Lee-Sherick AB, Huey MG, Lasater EA, Kirkpatrick GD, Stashko MA, Zhang W, Jordan CT, Kireev D, Wang X, Frye SV, Earp HS, Shah NP, Graham DK. Minson KA, et al. Among authors: lasater ea. JCI Insight. 2016 Mar;1(3):e85630. doi: 10.1172/jci.insight.85630. JCI Insight. 2016. PMID: 27158668 Free PMC article.
58 results